FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer
(April 23, 2018)
CancerConnect News: The Food and Drug Administration granted approvals to Opdivo (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About... Continue Reading
Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma
(January 25, 2018)
CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential... Continue Reading
FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma
(January 5, 2018)
CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma... Continue Reading
Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer
(November 9, 2017)
Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading
Latest Renal Cancer News By Stage
General Renal Cancer
Sorry, there are no articles available for this cancer stage.
More General Renal Cancer